Physician profile
John J Li
NPI 1487678041
$5,908.91
in general payments reported to CMS, 2019-2025
23 companies · $833 in 2025
The $833 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $427 · 2021: $758 · 2022: $1,326 · 2023: $862 · 2024: $591 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.95 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,315.37 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,074.12 | 2019-2025 | Dovato |
| Insmed, INC. | $694.45 | 2019-2025 | Arikayce, Brinsupri |
| Shionogi INC | $672.13 | 2021-2025 | Fetroja |
| Janssen Biotech, INC. | $382.78 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $303.04 | 2022-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $272.35 | 2019-2022 | |
| Abbvie INC. | $230.66 | 2021-2025 | |
| Janssen Products, Lp | $224.95 | 2019 | |
| Merck Sharp & Dohme LLC | $168.86 | 2019-2025 | Zerbaxa |
| Allergan, INC. | $165.45 | 2019 | |
| La Jolla Pharmaceutical Company | $86.99 | 2022-2025 | Xacduro, Xerava |
| Cipla USA INC. | $76.56 | 2022 | |
| Pfizer INC. | $44.06 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $28.08 | 2025 | Mytesi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.91 | 2024 | Xifaxan |
| Philips North America LLC | $23.90 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $20.96 | 2019 | |
| Mayne Pharma Commercial LLC | $19.67 | 2022 | |
| Lundbeck LLC | $18.54 | 2023 | Vyepti |
| Aimmune Therapeutics, INC. | $18.12 | 2025 | Vowst |
| Pharmacyclics LLC, An Abbvie Company | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.